ALS. Alzheimer's. Parkinson's. MS.
On a mission to reverse ALS — and beyond.
Hope Neuron is developing a non-drug, cell-based therapy to test and fight neurodegeneration at the cellular level. No stem cells. No pharmaceuticals. Just your body's own immune system reset to normal function.
Why This Matters Now
ALS kills motor neurons. The body's immune system — meant to protect — turns against it. Conventional medicine manages symptoms but doesn't stop the progression.
$1.8B market.
No cure or reversal…
until now.
Our Story
Hope Neuron started with one man watching his wife struggle with Alzheimer's.
Ronald Lane is a biologist with an engineer's mind and a husband's heart. When Alzheimer's began taking his wife Sandy, he didn't reach for existing treatments. He asked a different question: what if we could reset the immune system itself?
That question became a decade of research.
Today, the science is ready. HOPE-Neuron is in the late stages of developing the first non-drug, immune-reset platform for neurodegenerative disease, starting with ALS. The SELanetx™ system is a device-enabled, outpatient therapy that reprograms immune dysfunction at its root cause.
With strong preclinical results, globally protected IP, and academic partners in place, HOPE-Neuron is moving toward first-in-human trials. This raise puts investors in at the inflection point.
"What if we could reset the immune system itself?"
Choose Your Path
How do you want to explore this?
Understand the science.
How does it work? What does the research show? Is this real?
See the Science →Understand the opportunity.
What's the market? What's the traction? Why now?
See the Investment →The Evidence
The untreated mice fell off the treadmill. The treated ones kept running.
In our ALS preclinical study, SELanetx™ produced a measurable M1-to-M2 immune cell shift — the same mechanism we're targeting in humans. The result: improved motor function in ALS-model mice. p<0.008. That's not a promise. That's data.
SELanetx™
Not a drug. Not a stem cell. Something new.
SELanetx™ works by drawing a small amount of your blood, applying oxygen and pressure to activate a natural cellular process, and returning it — now carrying signals that tell your immune system to stop attacking and start healing. It's a 30-minute, closed-loop procedure that works without foreign substances or long-term pharmaceutical dependency.
Withdraw ~300ml of blood
A small sample — less than a typical blood donation — is drawn in a standard clinical setting.
Activate apoptotic cells via precision oxygen
A closed-loop device applies precise oxygen and pressure to activate cells that naturally signal your immune system to stand down.
Re-infuse. Immune system resets.
The treated blood is returned. Your immune system receives a signal to stop attacking and start healing — no foreign substances required.
Join the Campaign
We're raising $5M to take SELanetx™ into human trials.
The next study is at Barrow Neurological Institute. It's staffed and ready, pending this campaign. Every dollar moves us closer to a human trial for ALS. This is your chance to own a piece of that moment.
"I'm betting my own money on this. I hope you will too."
Beyond ALS
ALS is where we start. It's not where we stop.
MS. Alzheimer's. Parkinson's. Selected cancers. The same immune rebalancing mechanism that targets ALS is applicable across the spectrum of neurodegenerative disease.
- ALS Primary focus — advancing toward first-in-human trials at Barrow Neurological Institute.
- Alzheimer's The same immune rebalancing mechanism that targets ALS applies directly to Alzheimer's pathology.
- Multiple Sclerosis MS involves immune dysfunction at the root — SELanetx™ is designed for exactly this class of disease.
- Parkinson's Neuroinflammation drives Parkinson's progression; the platform targets that pathway.
- Selected cancers Immune modulation opens doors to oncology applications under active investigation.